CO - CO STOCK NEWS

Global Cord Blood Corporation (NYSE: CO) has announced the termination of discussions regarding the proposed merger with Cordlife Group Limited. This decision follows a non-binding proposal dated June 4, 2019, where Cordlife sought to combine its business with GCBC through a statutory merger. The boards of both companies have mutually agreed to discontinue any further negotiations related to this proposal. GCBC remains the largest cord blood banking operator in China, offering a range of services including cord blood collection and storage.

Global Cord Blood Corporation (NYSE: CO) has reported that China's National Health Commission has issued a new policy prohibiting the acceptance of applications for cord blood banking licenses in 2021. This decision aims to enhance public health and refine related policies. Currently, the company holds three existing licenses covering Beijing, Guangdong, and Zhejiang. The company warns shareholders about the lack of details regarding future regulatory changes in the sector and commits to issuing updates as necessary.

On December 7, 2020, Global Cord Blood Corporation (NYSE: CO) held its 2020 Annual General Meeting in Hong Kong. Shareholders ratified the re-appointment of KPMG Huazhen LLP as independent auditors for the financial year ending March 31, 2021, and re-elected Ms. Ting Zheng, Dr. Ken Lu, and Mr. Jack Chow as Class B directors until the 2023 annual meeting. GCBC is China's leading provider of cord blood services, offering collection, testing, and storage. The company emphasizes its growth and stability in the cord blood banking sector.

Global Cord Blood Corporation (NYSE: CO) reported its Q2 and first half fiscal 2021 results, showing a revenue decline of 8.9% YoY to RMB285.6 million ($42.1 million). New subscribers totaled 17,643, with an accumulated base reaching 867,180. Gross profit fell 9.1% YoY to RMB240.9 million ($35.5 million), while operating income decreased 3.7% YoY to RMB139.2 million ($20.5 million). However, net income increased 9.2% to RMB131.4 million ($19.4 million), aided by a mark-to-market gain in equity securities. The company remains focused on growth despite challenges from Covid-19 and a declining birth rate.

Global Cord Blood Corporation (NYSE: CO) has announced it will release its unaudited financial results for the second quarter and first half of fiscal year 2021 on November 24, 2020, after U.S. market close. A conference call to discuss these results will be held at 8:00 a.m. ET on November 25, 2020. Investors can access the call via the Company’s IR website or by phone. Global Cord Blood is the largest cord blood banking operator in China, providing essential services in cord blood collection and storage.

Global Cord Blood Corporation (NYSE: CO) announced its 2020 annual general meeting scheduled for December 7, 2020, at 9:00 p.m. Hong Kong Time. Shareholders of record by October 26, 2020, can vote during this meeting. The company emphasizes compliance with health regulations due to COVID-19, which may include temperature checks and face coverings for attendees. GCBC is China's largest umbilical cord blood banking operator, providing collection, laboratory testing, and storage services. More details are available in their annual report filed with the SEC.

Global Cord Blood Corporation (CO) reported its Q1 fiscal 2021 results, showing a 2.8% year-over-year revenue increase to RMB280.9 million ($39.8 million). New subscribers totaled 17,233, with a total base of 849,933. Gross profit rose 4.3% YoY to RMB237.5 million ($33.6 million), achieving a gross margin of 84.5%. Operating income climbed 18.8% YoY to RMB133.5 million ($18.9 million), while net income attributable to shareholders increased 22.3% YoY to RMB132.5 million ($18.8 million), reflecting strong operational control despite COVID-19 challenges.

Global Cord Blood Corporation (NYSE: CO), the leading provider of cord blood services in China, will release its financial results for Q1 fiscal 2021 on August 24, 2020, post-market. A conference call to discuss these results will occur on August 25, 2020, at 8:00 a.m. ET, accessible via the Company's investor relations website. The company is known for its comprehensive cord blood collection and storage services, operating the largest banking network in China. Supplemental financial data will also be available on its website and SEC filings.

Global Cord Blood Corporation (NYSE: CO) has filed its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission, detailing audited financial statements for the fiscal year ending March 31, 2020. As China's leading cord blood bank, GCBC offers comprehensive services including collection, testing, processing, and storage of stem cells. The Form 20-F is accessible via the SEC's website and GCBC's Investor Relations page. This filing underscores the company's commitment to transparency and regulatory compliance.